RxDoctor Payments Data

Syed Hussain, MD

Family Medicine · Jacksonville, FLNPI 1588750970

Payments from drug & device makers

$594in general payments, 2019–2025

Across 20 payments — averaging $29.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$132
  • AbbVie$122
  • Indivior Inc.$95
  • Orexo US, Inc.$87
  • Actelion Pharmaceuticals US, Inc.$30
  • Noven Therapeutics, LLC$25
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$594 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$105,682
Medicare patients
66
Services billed
2,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium22$77,477
MounjaroTirzepatide46$51,294
OzempicSemaglutide44$49,952
Diclofenac Sodium33$30,532
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl139$20,132
Combivent RespimatIpratropium/Albuterol Sulfate17$17,596
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen503$16,412
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,935
Xtampza ErOxycodone Myristate26$14,490
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen521$14,255
Lidocaine45$4,438
Gabapentin254$4,187
Oxycodone Hcl255$3,539
Lubiprostone23$3,409
Cyclobenzaprine Hcl79$3,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$49,95244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →